China Approves Rilzabrutinib for Persistent or Chronic ITP
China’s National Medical Products Administration approved Genzyme Corporation’s rilzabrutinib tablets, branded Sailizhi in China, for adults with persistent or chronic primary immune thrombocytopenia who respond inadequately to or cannot tolerate corticosteroids, immunoglobulin or other…
